Evidence map›Paper›PMID 39047210›Full record

ArticleBlood advances2024

NK- and T-cell repertoire is established early after allogeneic HSCT and is imprinted by CMV reactivation.

Antonia Schäfer, Zuleika Calderin Sollet, Marie-Priscille Hervé, Stéphane Buhler, Sylvie Ferrari-Lacraz, Paul J Norman, Katherine M Kichula, Ticiana D J Farias, Stavroula Masouridi-Levrat, Anne-Claire Mamez and 4 more

Abstract read
In one paragraph

Article in Blood advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Antonia SchäferTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.
Zuleika Calderin SolletTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.ORCID 0000-0001-5933-6412
Marie-Priscille HervéTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.
Stéphane BuhlerTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.
Sylvie Ferrari-LacrazTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.
Paul J NormanDepartment of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.
Katherine M KichulaDepartment of Biological Sciences, The University of North Carolina at Charlotte, Charlotte, NC.ORCID 0000-0002-9817-3043
Ticiana D J FariasDepartment of Biomedical Informatics and Department of Immunology and Microbiology, University of Colorado School of Medicine, Aurora, CO.ORCID 0000-0002-3606-2428
Stavroula Masouridi-LevratService of Haematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Anne-Claire MamezService of Haematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Amandine PradierService of Haematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Federico SimonettaService of Haematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.
Yves ChalandonService of Haematology, Department of Oncology, Geneva University Hospitals and Faculty of Medicine, University of Geneva, Geneva, Switzerland.ORCID 0000-0001-9341-8104
Jean VillardTransplantation Immunology Unit and National Reference Laboratory for Histocompatibility, Department of Diagnostic, Geneva Center for Inflammation Research, Geneva University Hospitals, Geneva, Switzerland.ORCID 0000-0003-2667-7506

Funding

Insights Into Immune-Related Diseases Born from Population GenomicsU01AI090905 · NIAID · UNIVERSITY OF COLORADO DENVER · PI Paul John Norman · 2010 to 2026
$10.9M
NIAID NIH HHS U01 AI090905
6 · The paper itself

Abstract

abstractBesides genetic influences, nongenetic factors such as graft-versus-host disease and viral infections have been shown to be important shapers of the immune reconstitution and diversification processes after hematopoietic stem cell transplantation (HSCT). However, differential susceptibility to immune modulation by nongenetic factors is not fully understood. We determined to follow the reconstitution of the T-cell receptor (TCR) repertoire through immune sequencing of natural killer (NK) cells using a 35-marker spectral flow cytometry panel and in relation to clinical events. A longitudinal investigation was performed on samples derived from 54 HSCT recipients during the first year after HSCT. We confirmed a significant contraction in TCR repertoire diversity, with remarkable stability over time. Cytomegalovirus (CMV) reactivation had the ability to significantly change TCR repertoire clonality and composition, with a long-lasting imprint. Our data further revealed skewing of NK-cell reconstitution in CMV reactivated recipients, with an increased frequency of KIR2DL2L3S2+ adaptive, cytolytic, and functional CD107a+ NK cells, concomitant with a reduced pool of NKG2A+ NK cells. We provided support that CMV might act as an important driver of peripheral homeostatic proliferation of circulating specific T and NK cells, which can be viewed as a compensatory mechanism to establish a new peripheral repertoire.

Indexed as

CytomegalovirusCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationKiller Cells, NaturalT-LymphocytesVirus ActivationAdultAgedFemaleHumansMaleMiddle AgedReceptors, Antigen, T-CellTransplantation, HomologousYoung AdultReceptors, Antigen, T-Cell

Identifiers

PMID39047210
PMCPMC11550366

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.